List view / Grid view
17 December 2013 | By GlaxoSmithKline
GSK sets out plans to evolve the way it sells and markets its products to healthcare professionals...
17 December 2013 | By Biogen Idec
Biogen Idec opts-in to commercialization opportunity with joint venture partner...
16 December 2013 | By GlaxoSmithKline
GSK intends to keep the Company publicly-listed...
16 December 2013 | By Boehringer Ingelheim,
"These data are encouraging as they demonstrate that HCV genotype-1 infected patients irrespective of the presence of the common HCV Q80K variant..."
13 December 2013 | By Daiichi Sankyo
Daiichi Sankyo Espha launched two new generic drugs with two new active ingredients and two generic drugs with an additional standard...
13 December 2013 | By AstraZeneca
Lesinurad is an investigational agent being studied as a selective uric acid re-absorption inhibitor that inhibits the URAT1 transporter...
12 December 2013 | By IFPAC
IFPAC is the essential meeting place for the latest developments in Process Analytical Technology...
12 December 2013 | By AstraZeneca
Advisory Committee recommends metreleptin for the treatment of paediatric and adult patients with generalised lipodystrophy...
12 December 2013 | By Merck
GRASTEK is the proposed trade name for the company’s investigational sublingual tablet for the treatment of Timothy grass induced allergic rhinitis...
12 December 2013 | By AstraZeneca
Dapagliflozin is being reviewed by the FDA for use as monotherapy, and in combination with other antidiabetic agents...
11 December 2013 | By KDM Communications
Quotient Clinical has been acquired from the Quotient Bioresearch Group by Bridgepoint Development Capital for an undisclosed sum...
11 December 2013 | By GlaxoSmithKline
Manufacturing sites in Ware, Hertfordshire and Worthing, Sussex will be upgraded with new state-of-the-art equipment...
10 December 2013 | By Teva
Amir Elstein to succeed Professor Moshe Many...
10 December 2013 | By Novo Nordisk
The reporting relates to the company’s receipt of a Complete Response Letter from the US Food and Drug Administration...
10 December 2013 | By Merck
The DMC recommendation was made following a planned analysis of interim safety data that included a safety cohort of 200 patients treated with MK-8931 for at least 3 months...
